Advertisement
Advertisement

RIGL

RIGL logo

Rigel Pharmaceuticals Inc. (New)

26.04
USD
Sponsored
-0.20
-0.76%
May 08, 15:59 UTC -4
Closed
exchange

Pre-Market

26.48

+0.44
+1.67%

Rigel Pharmaceuticals Inc. (New) Profile

About

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer.

Info & Links

CEO

Raul R. Rodriguez

Headquarters

611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.rigel.com

Auditor

Ernst & Young LLP

Share holders

28

Employees

174

Rigel Pharmaceuticals Inc. (New) Statistics

Valuation Measures

Market Capitalization2

489.86M

Enterprise Value

501.58M

Enterprise Value/EBITDA(ttm)

3.96

Price to Earnings Ratio(ttm)

4.69

Price to Sales(ttm)

1.92

Price to Book(mrq)

1.41

Price to Cash(ytd)

4.52

Profitability

Gross Margin(ttm)

92.98%

Operating Margin(ttm)

41.35%

Profit Margin(ttm)

126.07%

Return on Equity(ttm)

79.84%

Return on Invested Capital(ttm)

151.62%

Return on Assets(ttm)

42.74%

Income Statement

Revenue(ttm)

294.28M

Revenue Per Share(ttm)

15.93

Gross Profit(ttm)

274.66M

EBITDA(ttm)3

126.73M

Net Income Available to Common(ttm)

367.02M

Diluted EPS(ttm)

18.91

Share Statistics

Beta (5Y Monthly)

1.27

52-Week Change

38.73%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

18.47M

Dividend Yield

0.00%

Float4

16.73M

% Held by Insiders

9.48%

% Held by Institutions

66.23%

Balance Sheet

Total Cash(mrq)

154.96M

Total Cash Per Share(mrq)

8.39

Total Debt(mrq)

52.29M

Total Debt/Equity(mrq)

13.36%

Current Ratio(mrq)

2.42%

Quick Ratio(mrq)

2.30%

Book Value Per Share(mrq)

21.38

Cash Flow

Operating Cash Flow Per Share(ytd)

4.02

Free Cash Flow(ytd)

75.66M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement